Скачать или смотреть NVO Stock Shocks Investors w/ Unexpected Cautious Outlook for Sales

Novo Nordisk is down and a major topic of discussion following a trading halt and the release of its latest financial results, which included an unexpected cautious outlook for sales alongside a significant share buyback program. Novo, which makes the popular weight-loss and diabetes drugs Wegovy and Ozempic, expects sales to decline between 5% and 13% at constant exchange rates. This would mark a reversal from 10% sales growth last year. While Novo expects sales to rise internationally as Wegovy expands into more markets, U.S. sales will likely decline, the company said. Aside from competitive pressure from tirzepatide maker Lilly, there are other factors at play.

Reduced obesity coverage in Medicaid is one of them. While state Medicaid programs are required to cover most drugs approved by the Food and Drug Administration, federal law allows them to choose whether to cover weight-loss drugs.

Insurance coverage for GLP-1 medications for chronic obesity has been scant in the past, but it has continued to dwindle. Novo said it also expects its profit to take a hit from lower drug prices as part of the Trump administration's "most favored nation" pricing actions. The community is actively debating the future, balancing concerns over revised guidance with excitement about strong initial prescription numbers for its innovative oral weight-loss pill and positive data from its next-generation diabetes treatment.

Join this channel to get access to perks:
   / @equity4keeps  

Consider Supporting this Channel via PayPal: https://www.paypal.com/donate/?hosted...